

Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis.

Item Type	Journal article
Authors	Panoulas, Vasileios F.;Douglas, Karen M. J.;Milionis, Haralampos J.;Stavropoulos-Kalinoglou, Antonios;Nightingale, Peter;Kita, Marina D.;Tselios, Andreas L.;Metsios, Giorgos S.;Elisaf, Moses S.;Kitas, George D.
Citation	Rheumatology, 46 (9): 1477-82
DOI	10.1093/rheumatology/kem169
Publisher	Oxford University Press
Journal	Rheumatology
Download date	2026-05-11 09:11:53
Link to Item	http://hdl.handle.net/2436/40235

**PREVALENCE AND ASSOCIATIONS OF HYPERTENSION AND ITS CONTROL
IN PATIENTS WITH RHEUMATOID ARTHRITIS**

Vasileios F. Panoulas^{1,2}, Karen M.J. Douglas¹, Haralampos J. Milionis², Antonios Stavropoulos-Kalinoglou¹, Peter Nightingale³, Marina D. Kita¹, Andreas L. Tselios⁴, Giorgos S. Metsios¹, Moses S. Elisaf² and George D. Kitas¹

¹Department of Rheumatology, Dudley Group of Hospitals NHS Trust, Russells Hall Hospital, Dudley, West Midlands, UK

²Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece

³Wolfson Computer Laboratory, University Hospital Birmingham NHS Foundation Trust, Birmingham, UK

⁴Department of Cardiology, Dudley Group of Hospitals NHS Trust, Russells Hall Hospital, Dudley, West Midlands, UK

Number of words (main text): 3297

Number of words (abstract): 247

Number of tables: 2

Number of Figures: 2

Author for correspondence:

Professor George D. Kitas, MD, PhD, FRCP

Department of Rheumatology

Dudley Group of Hospitals NHS Trust

Russells Hall Hospital

Pensnett Road

Dudley, West Midlands, DY1 2HQ

United Kingdom

Tel. No. +44-1384-244842

Fax No. +44-1384-244808

E.mail: gd.kitas@dqoh.nhs.uk or g.d.kitas@bham.ac.uk

Abstract

Objective: Rheumatoid arthritis (RA) associates with excessive cardiovascular morbidity and mortality. Hypertension (HT) contributes significantly to the development of cardiovascular disease (CVD). Little is known about the factors that influence blood pressure (BP) in patients with RA. In this study, we assessed the prevalence of HT in a secondary care cohort of RA patients, and aimed to identify factors associated with its presence and inadequate control.

Methods: A total of 400 consecutive RA patients were studied. HT was defined as systolic BP \geq 140 mmHg and/or diastolic BP \geq 90 mmHg, or current use of antihypertensive drugs. The association of HT with several demographic and RA-related factors, co-morbidities and drugs was evaluated using logistic regression.

Results: HT was present in 282 (70.5%) patients. Of those, 171 (60.6%) received antihypertensive therapy, but 111 (39.4%) remained undiagnosed. Of those treated, only 37/171 (21.8%) were optimally controlled. Multivariable logistic regression revealed age (OR=1.054, CI: 1.02 to 1.07, $p=0.0012$), BMI (OR=1.06, CI: 1.003 to 1.1213, $p=0.038$) and prednisolone use (OR=2.39, CI: 1.02 to 5.6, $p=0.045$) to be independently associated with the presence of HT. BMI (OR=1.11, CI: 1.02 to 1.21, $p=0.002$) and the presence of CVD (OR=4.01, CI: 1.27 to 12.69, $p=0.018$) associated with uncontrolled HT.

Conclusions: HT is highly prevalent in RA, under-diagnosed particularly in the young, and under-treated particularly in old RA patients with CVD. RA patients receiving steroids should be specifically targeted for screening and treatment; those with any cardiovascular co-morbidity may require particularly aggressive monitoring and treatment strategies.

Keywords: hypertension, rheumatoid arthritis, prevalence, cardiovascular, control

Introduction

Rheumatoid arthritis (RA) associates with increased cardiovascular mortality due to increased prevalence of co-morbidities such as Myocardial Infarction (MI), stroke and Heart Failure (HF) [1,2]. The adjusted relative risk of MI in women with RA compared to those without RA is estimated to be around 2.0 [2], while acute coronary syndromes may present atypically and recur more frequently in patients with RA [3]. Increased clinical suspicion may aid early identification and appropriate management of risk factors in these patients [1].

HT is quantitatively the most important modifiable risk factor for cardiovascular disease (CVD), being more common than cigarette smoking, dyslipidaemia, or diabetes [4]. In the INTERHEART study [5], which included patients from 52 countries, HT accounted for 18% of the population attributable risk of a first MI. HT increases the risk of both coronary artery disease and cerebrovascular disease in the general population [6]. It remains unclear whether HT is commoner in RA [7-9].

Aging and obesity are known predictors of HT in the general population; smoking cessation and low grade inflammation may also contribute to the development of HT [10]. In RA, the chronic inflammatory burden may lead to increased arterial stiffness [11], one of the physical causes of raised systolic BP, providing a potential link between inflammation and HT in this disease. Drugs commonly administered to RA patients, such as the non Steroidal Anti-Inflammatory Drugs (NSAIDs), cyclo-oxygenase II inhibitors (Coxibs) [12], oral steroids [13] and some disease-modifying anti-rheumatic drugs (DMARDs), such as leflunomide [14] and cyclosporin [15] may also cause major or minor increments in BP levels. Co-morbidities common in RA, such as insulin resistance [16], dyslipidaemia [17] and renal disease, have also been shown to associate with essential HT in the general

population [18,19]. To date, no studies have investigated the potential association of HT with these factors in patients with RA.

In the present study we aimed: (i) to identify the overall prevalence of HT in a large secondary care population with RA, and estimate whether undiagnosed and/or sub-optimally controlled HT is a common problem in these patients; and (ii) to identify factors that may associate with the presence and/or insufficient control of HT in RA.

Patients and Methods

Four hundred consecutive patients with RA meeting retrospective application of the 1987 revised ACR criteria [20], attending routine outpatient clinics at the Department of Rheumatology of the Dudley Group of Hospitals, Dudley (Black Country), West Midlands, UK, were enrolled in this cross-sectional, one-centre study. The study had local Research Ethics Committee and Research and Development approval and all participants gave their written informed consent according to the Declaration of Helsinki.

Basic demographic and clinical characteristics of the study population are shown in Table 1. All participants underwent a thorough baseline evaluation including a detailed review of their medical history and hospital records, physical examination, and contemporary assessments of height, weight, body mass index (BMI), body composition (using a TANITA Body Composition Analyzer BC-418), current disease activity score (DAS28) [21] and physical function using the Health Assessment Questionnaire (HAQ) [22]. All medications and their exact indication were recorded, including loop and thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors (ACE-I) and Angiotensin-II receptor antagonists (ARBs), dihydropyridine and non-dihydropyridine calcium channel blockers, α -adrenoreceptor blockers, centrally acting antihypertensives, other antihypertensives, oral daily prednisolone,

paracetamol, NSAIDs, Coxibs and DMARDs. **Oral prednisolone dose was defined as low if <7.5mg/day, medium if ≥7.5mg/day and high if >30mg/day [23].**

Blood pressure (BP) was the mean of three measurements taken at five minute intervals on the right arm with the patient in a seated position after at least five minutes rest, using an appropriately sized cuff of the CRITICARE 506DXN machine (Systems Inc). The presence of HT was defined as a systolic BP≥140 and/or diastolic BP≥90 and/or the use of antihypertensive medications, according to the British HT Society/NICE guidelines [24]. Patients were divided in two main groups: normotensives and hypertensives. Those with HT were sub-divided into: ***controlled HT*** [if they were receiving medication specifically prescribed for HT and had SBP<140 mmHg and DBP<90 mmHg (if they had no CVD or diabetes mellitus-DM) or SBP<130 mmHg and DBP<80 mmHg (if they had CVD or DM)]; ***uncontrolled HT*** (if SBP or DBP were higher than the above values while on treatment); ***untreated HT*** (if SBP≥140 mmHg or DBP≥90 and the patient was not on anti-hypertensive therapy).

Patients were classified as having CVD (RA+CVD) if they had a positive history of any of the following: MI, stroke or Transient Ischaemic Attack (TIA), Peripheral Vascular Disease (PVD), angioplasty, coronary artery bypass grafting (CABG), or if they had a positive Rose questionnaire [25] on assessment. Patients were defined as being diabetic when fasting glucose levels were >7mmol/L and/or oral hypoglycemic medication or insulin was used. Number of pack-years of smoking was recorded and patients were categorised as current smokers, ex smokers, never smoked.

Venous blood was collected in the fasting state on the same day and a wide range of tests was performed. All biochemical tests were carried out in the Biochemistry Laboratory of Russells Hall hospital, Dudley Group of hospitals NHS Trust, UK. Biochemical estimations included: fasting lipids, complete serum biochemistry, fasting glucose, fasting insulin and C-reactive protein (CRP). Insulin

Resistance (IR) was evaluated from fasting glucose and insulin using the Homeostasis Model Assessment of IR (HOMA IR) [26] and the Quantitative Insulin sensitivity Check Index (QUICKI)[27], and was defined as the presence of DM or HOMA IR ≥ 2.5 or QUICKI ≤ 0.333 . Renal function was assessed by GFR estimation using the six-variable Modification of Diet in Renal Disease (MDRD) equation [28].

Statistical analysis

The Kolmogorov-Smirnov test was used to evaluate whether each parameter followed a Gaussian distribution. Values were expressed as mean \pm standard deviation (SD), median (25-75th percentile values) or percentages, as appropriate. Comparisons were performed by Student's t-test, Mann Whitney U test, and Chi-square test for normally distributed, non-normally distributed and categorical variables, respectively.

Binary logistic regression analysis was used to evaluate the independence of the factors associated with HT status and the differences between the "controlled HT" and "uncontrolled HT" groups.

Differences were considered to be significant at a p value of <0.05 (two-tailed). All analyses were carried out with SPSS 13.0 (SPSS Inc, Chicago, Illinois).

Results

Descriptive characteristics of the population studied:

The cohort consisted almost exclusively (96%) of Caucasians (reflecting the local demographic split) and were predominantly (~73%) females. The mean age (SD) was 61.56 ± 12.02 years, and the mean \pm SD systolic and diastolic BP were 142.24 ± 20.74 and 78.85 ± 11.24 mmHg respectively.

Of the 400 patients, 350 (87.5%) were on DMARDs: 225 (56.3%) on methotrexate, 118 (29.5%) on sulphasalazine, 80 (20%) on hydroxychloroquine, 46 (11.5%) on anti Tumor Necrosis Factor alpha (anti-TNF α) therapy, 16 (4%) on

leflunomide, 7 (1.8%) on azathioprine, and 2 (0.5%) on cyclosporin; 227 (56.8%) patients were on DMARD monotherapy, while 123 (30.8%) were on combination therapy of two or more DMARDs. One hundred and twenty five patients (31.3%) were taking daily oral prednisolone, **54 (13.4%) low dose, 71 (17.9%) medium dose and 0 (0%) high dose**; 79 (19.8%) NSAIDs and 32 (8%) Coxibs.

There were 118 (29.5%) normotensive and 282 (70.5%) hypertensive patients (male vs. female: 79.6% vs. 67.1%, $p=0.015$). From those with hypertension, 171 (60.6%) had been diagnosed and were on antihypertensive medications and 111 (39.4%) had undiagnosed/untreated HT (males vs. females; 35.3% vs. 41.3, $p=6.37$). Undiagnosed/untreated HT was significantly commoner in the younger age groups (35-44 years: 76.2%; 45-54 years: 51.6%) than in older age deciles (55-64 years: 34.5%; 65-74 years: 37.9%; 75+ years: 25%) ($p=0.003$) (Figure 1). From the 171 diagnosed hypertensives on treatment, 37 (21.63%) had controlled HT and 134 (78.36%) had uncontrolled HT. Uncontrolled HT was more common in older ($p=0.003$ – **Figure 1**) and overweight/obese patients ($p=0.029$ – **Figure 2**). Average control rate (controlled HT divided by total HT) was 37/282 (13.12%). This was very poor in the younger age group (35-44 years: 4.8%) and older age groups (65-74 years: 10.7%; 75+ years: 7.5%), and poor in the middle-aged patients (45-54 years: 19.4%, 55-64 years: 19%).

Differences according to hypertensive status:

Hypertensive RA patients, when compared to normotensives, were older [65.35 (57.55-71.22) vs. 58.86 (46.82-66) years, $p<0.001$], more often male (30.5% vs. 18.6%, $p=0.015$), had higher BMI (28.27 ± 4.98 vs. 26.42 ± 4.9 , $p=0.001$), were more often past cigarette smokers (43.5% vs. 26.7%, $p=0.005$) and users of **medium** dose prednisolone (21.5% vs. 9.3%, $p=0.004$), and were more likely to have IR [(44.7% vs. 22.3%, $p<0.001$): diabetes 8.9% vs. 2.5%, $p=0.015$; HOMA IR 2.06 (1.27-3.52) vs. 1.52 (0.93-2.37), $p<0.001$; QUICKI 0.34 (0.32-0.37) vs. 0.36 (0.33-

0.39), $p < 0.001$]. They also had higher lipid levels [TCHOL (5.54 ± 1.16 vs. 5.26 ± 1 mmol/L, $p = 0.032$) and TG 1.3 ($1-1.6$) vs. 1.1 ($0.9-1.5$) mmol/L, $p = 0.013$] and worse renal function (79.13 ± 21.63 vs. 88.56 ± 18.76 ml/min/ 1.73m^2 , $p < 0.001$). There were no significant differences between hypertensive and normotensive RA patients in the levels of current inflammation (ESR, CRP, DAS28), physical dysfunction (HAQ) or the use of NSAIDs, Coxibs, leflunomide or other DMARDs.

Patients with uncontrolled HT, compared to those with controlled HT, were not significantly older (66.22 ± 10.32 vs. 62.7 ± 9.28 years, $p = 0.06$), but had significantly higher BMI (28.97 ± 5.12 vs. 26.87 ± 4.83 , $p = 0.03$) and prevalence of CVD (36.8% vs. 13.5% , $p = 0.007$). ACE-I/ARBs were used more frequently in the uncontrolled HT group compared to patients with controlled HT (63.9% vs. 45.9% , $p = 0.049$); there were no differences in any of the other classes of anti-hypertensive drugs (Table 2).

Multivariable analysis

A logistic regression model including age, sex, BMI, smoking habit, total cholesterol, TG, IR, full MDRD, use of **medium** dose prednisolone, NSAIDs/Coxibs, leflunomide and statins was utilized in order to evaluate which factors were independently associated with the presence of HT. Variables that retained significance were age (OR=1.05, CI: 1.02 to 1.07, $p < 0.001$), BMI (OR=1.06, CI: 1.003 to 1.121, $p = 0.038$) and use of **medium** dose prednisolone (OR=2.39, CI: 1.02 to 5.6, $p = 0.045$).

A similar approach was used to identify factors that may associate with sub-optimal BP control in RA patients. The basic model included age and sex, the factors that were significant in the univariable analysis above (BMI and presence of CVD) and the four main classes of antihypertensive drugs (thiazide diuretics, b-blockers ACE-I and dihydropyridine calcium channel blockers). Increasing BMI (OR=1.11, CI: 1.02 to 1.21, $p = 0.018$) and presence of CVD (OR=4.01, CI: 1.27 to 12.69, $p = 0.018$)

retained their significant association with sub-optimal BP control, while no other factors transpired as being significant.

Discussion

The overall prevalence of HT in this secondary care cohort of RA patients with a mean age of 62 years was high at 70%: this is higher even than the highest HT prevalence in England, observed in those over 75 years of age in the 2003 National Health Survey for England (NHSE) [29], and appears to be present consistently in both male and female RA patients of all age groups. In our study, assessment of BP was based on the mean of three clinic measurements: this may not be as reliable as 24h BP monitoring, which can rule out cases of white-coat HT [30]. However, the NHSE was also based on 3 BP measurements to define HT, so the increased prevalence observed in our cohort could not be due to such misclassification. The NHSE was community-based, whereas our cohort was exclusively from secondary care, thus the prevalence of HT in the overall population of RA patients may have been overestimated. In addition, our study did not assess local population controls. It is well-established that the prevalence of HT may vary from locality to locality, with northern UK regions having higher HT rates than regions in the South in both sexes after standardization for age [31]. However, a recent survey from the geographically neighbouring (<6 miles) Wolverhampton, also in the Black Country, estimated the overall prevalence of HT in the adult non-diabetic local population at 28%, virtually identical with the national average [32].

A significant proportion of hypertensive RA patients in this cohort (35% of males and 41% of females) were undiagnosed and thus untreated. Again this is higher than the NHSE (males 6.4%-33.1%, females 1.7%-33.9%) and is quite disappointing, since RA patients are both regular attendees to hospital clinics and frequent users of primary care services [33], so they have ample opportunity to be monitored for their BP. It is particularly alarming that undiagnosed HT was much

commoner in the young RA patients, i.e. those who have most to benefit by early identification and treatment. Even in those patients who were diagnosed and treated for HT, the control rate was significantly lower, at 13.2%, than that observed in general population hypertensive males (21.5%) and females (22.8%) [34]. In the younger patients, this poor control rate was predominantly due to the fact that they remained undiagnosed, whereas in the older patients and those with CVD, it was because desirable targets were not met, probably due to either sub-optimal therapy or lack of adherence [35], both of which may result from the polypharmacy that characterizes many patients with RA [36]. We used a stricter definition of optimal control (<140/90 mmHg for patients without DM or CVD, <130/80 mmHg for those with DM or CVD) compared to that used in the NHSE (<140/90 mmHg, regardless of the presence of DM or CVD), but even applying the same definition, the proportion of RA patients with sub-optimal BP control was considerable. Optimal antihypertensive therapy has been associated with 40% mean reductions in stroke incidence, 20% in MI and more than 50% in heart failure [37] in the general population. Such an additional burden of uncontrolled hypertension may lead to additional strokes and MIs and explain part of the increased cardiovascular morbidity and mortality of RA. Similarly increased HT prevalence and poor control was also a characteristic of patients with type 2 DM, but the implementation of aggressive, systematic screening and management in this patient group appears to have improved BP control [38] and overall cardiovascular outcomes [39] in the last decade. The parallels between RA and type II DM, in the context of CVD, have been previously drawn [1] with a suggestion that equally aggressive screening and management programs should be established for RA patients. Regular CVD risk assessment has now been formally proposed by the Arthritis and Musculoskeletal Alliance (ARMA) [40] as one of the standards of care for RA patients, but does not appear to have become common practice yet [40], at least in the UK.

One of the main aims of the present study was to identify factors that may associate with HT in RA: this may be useful both for future pathogenic studies and for the identification of patients that may need to be specifically targeted for screening and intervention in the routine clinical setting. Significant univariable associations were found with previous smoking habit and with insulin resistance, mirroring what has previously been described in the general population [10]. However, these associations did not remain robust in multivariable analysis, which suggested that these associations may have been mediated through increasing BMI. This is in agreement with other studies in the general population, which show that overweight and obesity are important mediators of hypertension, in the context of ex-smokers [41] with insulin resistance [42], and associate with current or future HT and relevant end-organ damage in non-RA populations. Indeed the only demographic / anthropometric characteristics that remained strongly independently associated with HT in this RA cohort were advancing age and increasing obesity. The latter may be particularly important, as it has recently been suggested that the cut-offs for the classification of RA patients into overweight and obese categories should be lowered to a BMI of 23 and 28 respectively, to reflect their altered body composition [43].

Polypharmacy is a characteristic of many patients with RA [36] and many of the drugs used have the potential to cause major or minor increments in BP levels. In the present study there was no obvious association between HT and the use of either NSAIDs/Coxibs or relevant DMARDs (leflunomide and cyclosporin). The latter may be simply due to the very small number of patients receiving these drugs in the cohort studied. The former is more difficult to explain, as the evidence for their association with HT is compelling [1,12]. The exact frequency and dosing regimen prescribed was available, but the exact way these drugs were actually used by patients was not investigated or even recorded in detail in this study: it is well known that adherence to therapy may be low in RA in routine clinical practice, in contradistinction to randomized controlled trials which usually associate with high(er)

adherence rates [35]. However, the most important reason may be the cross-sectional design of this study, which leads to conclusions that can only serve for hypothesis-generation, than provide proof of causality or directionality of any of the associations found. A good example of this is the significant association found in this cohort between HT and the use of **medium** dose (≥ 7.5 mg/day) of oral prednisolone, but not with any of the laboratory or clinical assessments of current inflammation that were used (ESR, CRP or DAS28). This association could be either due to possible hypertensive effects of steroids, or due to the selection of patients with high inflammatory burden who require steroids for disease control. Indeed there is conflicting evidence for both in the literature. Studies have correlated raised endogenous cortisol levels and high BP [44], though not in patients with RA. In 129 asthmatic and 66 RA patients it has been suggested that “low” dose prednisolone (defined to be < 20 mg/day) cannot cause significant BP increments [13]. The link between steroid exposure and HT is not well understood [44], but increased peripheral vascular sensitivity to adrenergic agonists [45], increased hepatic production of renin substrate (angiotensinogen) and activation of renal tubular type 1 (mineralocorticoid) receptors by cortisol [46] have all been proposed as potential mechanisms. However, increased levels of systemic inflammation have also been associated with HT in the general population. A prospective cohort study [47] has recently demonstrated that CRP levels associate with future development of HT. Increased inflammatory load has been associated with worse overall and CVD outcomes in RA [1,48], but not directly with HT. We have not collected “historical” data of the extent of systemic inflammation in relation to when HT developed in the RA patients of this cohort, but it would be interesting to study this in prospective cohorts of inflammatory arthritis, such as the Norfolk Arthritis Register (NOAR) [49] or others.

Finally, the present study aimed to identify factors that may associate with sub-optimal BP control in patients with RA. Robust associations were found between

uncontrolled BP, increasing BMI and the presence of CVD, the latter because target BP is lower (<130/80) than general (<140/90). This would suggest that older, overweight RA patients with prevalent CVD should be specifically targeted for aggressive monitoring and treatment of their BP. This may be particularly difficult in these patients: none of the antihypertensive medications in the present study appeared to be superior to the others and the increased frequency of usage of ACE-I/ARB in uncontrolled hypertensive RA patients may simply mirror the higher rates of prevalent CVD and DM. It is likely that these patients require combination antihypertensive therapy, with very close monitoring due to their polypharmacy [36], co-morbidities [50] and adherence characteristics [35].

In conclusion, this cross sectional study suggests an increased prevalence and low control rates of HT in secondary care RA patients compared to the general population of England. This may be of importance in the context of the increased cardiovascular morbidity and mortality of RA. Systems for surveillance, adequate treatment and ongoing monitoring for these patients need to be put in place both in primary and secondary care. The young, and elderly overweight RA patients should be specifically screened for undiagnosed HT, while those with prevalent CVD need aggressive monitoring and treatment strategies to achieve recommended BP targets [51].

Acknowledgments/Funding

This study was funded by the Dudley Group of Hospitals R&D Directorate cardiovascular program grant. The Department of Rheumatology is in receipt of infrastructure support from the Arthritis Research Campaign (grant number: 17682). Dr V.Panoulas is supported by a PhD scholarship from Empirikion Institute, Athens, Greece.

Reference List

1. Kitas GD, Erb N: Tackling ischaemic heart disease in rheumatoid arthritis. *Rheumatology* 2003, 42:607-613.
2. Solomon D, Karlson E, Rimm E, Cannuscio C, Mandl M: Cardiovascular morbidity and mortality in women diagnosed with Rheumatoid arthritis. *Circulation* 2003, 107:1303-1307.
3. Douglas KMJ, Pace A, Treharne GJ, Saratzis A, Nightingale P, Erb N, *et al.*: Excess recurrent cardiac events in rheumatoid arthritis patients with acute coronary syndrome. *Annals of the Rheumatic Diseases* 2005, 65:348-353.
4. Wilson PW: Established risk factors and coronary artery disease: the Framingham Study. *Am J Hypertens* 1994, 7:7S-12S.
5. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, *et al.*: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *Lancet* 2004, 364:937-952.
6. Prospective Studies Collaboration: Age specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet* 2006, 360:1903-1913.
7. McEntegart A, Capell HA, Czeran D, Rumley A, Woodward M, Lowe GDO: Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. *Rheumatology* 2001, 40:640-644.
8. Erb N, Pace AV, Douglas KMJ, Banks MJ, Kitas GD: Risk assessment for coronary heart disease in rheumatoid arthritis and osteoarthritis. *Scand Journal of Rheumatology* 2004, 33:293-299.
9. Solomon DH, Curhan GC, Rimm EB, Cannuscio CC, Karlson EW: Cardiovascular risk factors in women with and without rheumatoid arthritis. *Arthritis Rheum* 2004, 50:3444-3449.
10. Niskanen L, Laaksonen DE, Nyyssonen K, Punnonen K, Valkonen VP, Fuentes R, Tuomainen TP, Salonen R, Salonen JT: Inflammation, abdominal obesity, and smoking as predictors of hypertension. *Hypertension* 2004, 44:859-865.
11. Klocke R, Cockcroft JR, Taylor GJ, Hall IR, Blake DR: Arterial stiffness and central blood pressure, as determined by pulse wave analysis, in rheumatoid arthritis. *Annals of the Rheumatic Diseases* 2003, 62:414-418.
12. Aw TJ, Haas SJ, Liew D, Krum H: Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. *Arch Intern Med* 2005, 165:490-496.
13. Jackson SH, Beevers DG, Myers K: Does long-term low-dose corticosteroid therapy cause hypertension? *Clin Sci (Lond)* 1981, 61 Suppl 7:381s-383s.
14. Rozman B, Praprotnik S, Logar D, Tomsic M, Hojnik M, Kos-Golja M, *et al.*: Leflunomide and hypertension. *Ann Rheum Dis* 2002, 61:567-569.

15. Marra CA, Esdaile JM, Guh D, Fisher JH, Chalmers A, Anis AH: The effectiveness and toxicity of cyclosporin A in rheumatoid arthritis: longitudinal analysis of a population-based registry. *Arthritis Rheum* 2001, 45:240-245.
16. Dessein PH, Joffe BI, Stanwix AE: Inflammation, Insulin Resistance, and Aberrant Lipid Metabolism as Cardiovascular Risk Factors in RA. *J Rheumatol* 2003, 30:1403-1405.
17. Situnayake R.D., Kitas G.: Dyslipidaemia and rheumatoid arthritis. *Annals of the Rheumatic Diseases* 1997, 56:341-342.
18. Adamczak M, Zeier M, Dikow R, Ritz E: Kidney and hypertension. *Kidney Int Suppl* 2002,62-67.
19. Eckel RH, Grundy SM, Zimmet PZ: The metabolic syndrome. *Lancet* 2005, 365:1415-1428.
20. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, *et al.*: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* 1988, 31:315-324.
21. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL: Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. *Arthritis & Rheumatism* 1995, 38:44-48.
22. Kirwan JR, Reeback JS: Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. *Br J Rheumatol* 1986, 25:206-209.
23. Buttgereit F, da Silva JA, Boers M, Burmester GR, Cutolo M, Jacobs J, *et al.*: Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. *Ann Rheum Dis* 2002, 61:718-722.
24. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, Sever PS, McG TS: Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. *J Hum Hypertens* 2004, 18:139-185.
25. Heyden S, Bartel AG, Tabesh E, Cassel JC, Tyroler HA, Cornoni JC, Hames CG: Angina pectoris and the Rose questionnaire. *Arch Intern Med* 1971, 128:961-964.
26. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 1985, 28:412-419.
27. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, *et al.*: Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. *J Clin Endocrinol Metab* 2000, 85:2402-2410.

28. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. *Ann Intern Med* 1999, 130:461-470.
29. Epidemiology and Public Health at the Royal Free and University College Medical School. Commissioned by Department of Health: Health survey for England 2003. *Department of Health* 2004.
30. Myers MG: Ambulatory blood pressure monitoring for routine clinical practice. *Hypertension* 2005, 45:483-484.
31. Beevers D.Gareth, Lip Y Gregory, O'Brien Eoin: *ABC of hypertension (fifth edition)*. 2007.
32. Baskar V, Kamalakannan D, Holland MR, Singh BM: Hypertension in diabetes: is there a place for age-adjusted centile cut-offs in those aged <50 years? *QJM* 2004, 97:747-753.
33. Luqmani R, Hennell S, Estrach C, Birrell F, Bosworth A, Davenport G, *et al.*: British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Rheumatoid Arthritis (The first 2 years). *Rheumatology (Oxford)* 2006.
34. Primatesta P, Poulter NR: Improvement in hypertension management in England: results from the Health Survey for England 2003. *J Hypertens* 2006, 24:1187-1192.
35. Treharne GJ, Lyons AC, Hale ED, Douglas KMJ, Kitas GD: Predictors of medication adherence in people with rheumatoid arthritis: studies are necessary but non-validated measures of medication adherence are of concern. *Rheumatology* 2005, 44:1330.
36. Douglas KM, Iwaszko J, Treharne GJ, Sandhu R, Erb N, Kitas GD: Polypharmacy in patients with rheumatoid arthritis. *Musculoskeletal care*, in press.
37. Neal B, MacMahon S, Chapman N: Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. *Lancet* 2000, 356:1955-1964.
38. Campbell SM, Roland MO, Middleton E, Reeves D: Improvements in quality of clinical care in English general practice 1998-2003: longitudinal observational study. *BMJ* 2005, 331:1121.
39. Booth GL, Kapral MK, Fung K, Tu JV: Recent trends in cardiovascular complications among men and women with and without diabetes. *Diabetes Care* 2006, 29:32-37.
40. ARMA Standards of Care: patients' experiences
[\[www.rheumatoid.org.uk/download.php?asset_id=90\]](http://www.rheumatoid.org.uk/download.php?asset_id=90)

41. Puddey IB, Vandongen R, Beilin LJ, English DR, Ukich AW: The effect of stopping smoking on blood pressure--a controlled trial. *J Chronic Dis* 1985, 38:483-493.
42. Yokoyama H, Emoto M, Fujiwara S, Motoyama K, Morioka T, Komatsu M, et al.: Quantitative insulin sensitivity check index and the reciprocal index of homeostasis model assessment are useful indexes of insulin resistance in type 2 diabetic patients with wide range of fasting plasma glucose. *J Clin Endocrinol Metab* 2004, 89:1481-1484.
43. Stavropoulos-Kalinoglou A, Metsios GS, Koutedakis Y, Nevill AM, Douglas KM, Jamurtas A, et al.. Redefining overweight and obesity in rheumatoid arthritis patients. *Ann Rheum Dis* . 8-2-2007.
44. Whitworth JA: Adrenocorticotrophin and steroid-induced hypertension in humans. *Kidney Int Suppl* 1992, 37:S34-S37.
45. Walker BR, Best R, Shackleton CH, Padfield PL, Edwards CR: Increased vasoconstrictor sensitivity to glucocorticoids in essential hypertension. *Hypertension* 1996, 27:190-196.
46. Soro A, Ingram MC, Tonolo G, Glorioso N, Fraser R: Evidence of coexisting changes in 11 beta-hydroxysteroid dehydrogenase and 5 beta-reductase activity in subjects with untreated essential hypertension. *Hypertension* 1995, 25:67-70.
47. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM: C-reactive protein and the risk of developing hypertension. *JAMA* 2003, 290:2945-2951.
48. Stevens RJ, Douglas KMJ, Saratzis AN, Kitas GD: Inflammation and atherosclerosis in rheumatoid arthritis. *Exp Rev Mol Med* 2005, 7:1-24.
49. Symmons DP, Silman AJ: The Norfolk Arthritis Register (NOAR). *Clin Exp Rheumatol* 2003, 21:S94-S99.
50. Mikuls TR, Saag KG: Comorbidity in rheumatoid arthritis. *Rheumatic Disease Clinics of North America* 2001, 27:283-303.
51. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. *Heart* 2005, 91 Suppl 5:v1-52.

Table 1: Demographic, clinical and laboratory characteristics of the study population

	Total (N=400)	no HTN (N=118)	HTN (N=282)	p value
General demographics				
Age (years)	63.1 (55.5-69.6)	58.86 (46.82-66)	65.35 (57.55-71.22)	<0.001
Sex female n(%)	292 (73)	96 (81.4)	196 (69.5)	0.015
Smoking status n(%)				
never smoked	171 (45)	59 (50.9)	117 (42.4)	0.005
ex smokers	145 (38.2)	31 (26.7)	120 (43.5)	
current smokers	64 (16.8)	26 (22.4)	39 (14.1)	
Pack years	3 (0-20)	0.5 (0-20)	5 (0-20)	NS
RA characteristics				
General characteristics				
RF positive n(%)	296 (75.7)	86 (74.8)	210 (76.1)	
antiCCP positive n(%)	198 (66.4)	51 (63.8)	147 (67.4)	NS
Disease duration (years)	10 (4-18)	9.5 (4-17.25)	10 (4-19)	NS
Disease activity				
CRP (mg/L)	8 (5-20)	9 (4-18.25)	8 (5-20)	NS
ESR	21 (9-36.5)	9 (5-17)	10 (5-22)	NS
DAS 28	4.21±1.4	4.23±1.49	4.21±1.37	NS
Disease severity				
HAQ	1.5 (0.63-2.13)	1.63 (0.59-2)	1.5 (0.63-2.25)	NS
EAD n(%)	269 (67.3)	77 (65.3)	192 (68.1)	NS
Joint replacement surgery n(%)	116 (29)	37 (31.4)	79 (28)	NS
Medication				
DMARDs n(%)	350 (87.5)	104 (88.1)	246 (87.2)	NS
MTX n(%)	225 (56.3)	71 (60.2)	154 (54.6)	NS
antiTNF n(%)	46 (11.5)	14 (11.9)	32 (11.3)	NS
leflunomide n (%)	16 (4)	6 (5.1)	10 (3.5)	NS
prednisolone n(%)	125 (31.3)	28 (23.7)	97 (34.4)	0.036
prednisol medium dose n(%)	71 (17.9)	11 (9.3)	60 (21.5)	0.004
NSAID n(%)	79 (19.8)	27 (22.9)	52 (18.4)	NS
COX II inhibitors n(%)	32 (8)	10 (8.5)	22 (7.8)	NS
statin n(%)	78 (19.5)	10 (8.5)	68 (24.1)	<0.001
Comorbidities				
Dyslipidaemia				
Hypercholesterolaemia history n(%)	78 (19.5)	12 (10.2)	66 (23.4)	0.002
Total CHOL mmol/L ¹	5.44±1.15	5.26±1	5.54±1.16	0.032
TG mmol/L ¹	1.2 (0.9-1.6)	1.1 (0.9-1.5)	1.3 (1-1.6)	0.013
HDL mmol/L ¹	1.6 (1.3-1.9)	1.5 (1.3-1.8)	1.6 (1.3-1.9)	NS
LDL mmol/L ¹	3.24±1.15	3.13±1.09	3.3±1.17	NS
Insulin resistance				
IR n(%)	147 (38.2)	25 (22.3)	122 (44.7)	<0.001
DM n(%)	28 (7)	3 (2.5)	25 (8.9)	0.015
Glc mmol/L	4.9 (4.6-5.375)	4.8 (4.5-5.2)	5 (4.6-5.48)	0.009
Insulin pmol/L	60.05 (41.28-102.75)	53.05 (34.18-76.43)	66.5 (43.78-118)	0.001
HOMA IR	1.96 (1.25- 3.35)	1.55 (1.01-2.42)	2.09 (1.33-3.72)	0.001
QUICKI	0.35 (0.32-0.37)	0.36 (0.33-0.38)	0.34 (0.31-0.37)	0.001
Renal function				
Full MDRD	82±21.24	88.56±18.76	79.13±21.63	<0.001
Obesity				
BMI	27.67±5.03	26.42±4.9	28.27±4.98	0.001

Results expressed as percentages, median (25-75th percentile values) or mean ± SD as appropriate

NS: non significant, RA: Rheumatoid Arthritis, RF: Rheumatoid factor, Anti-CCP: Anti-Cyclic Citrullinated Peptide, CRP: C-Reactive Protein, ESR: Erythrocyte Sedimentation Rate, DAS: Disease Activity Score, HAQ: Health Assessment Questionnaire, EAD: Extra-Articular Disease, DMARDs: Disease Modifying Anti Rheumatic Drugs, MTX: Methotrexate, TNF: Tumor Necrosis Factor, CHOL: Cholesterol, TG: Triglycerides, HDL: High Density Lipoprotein, TC: Total Cholesterol, LDL: Low Density Lipoprotein, IR: Insulin resistance, DM: Diabetes Mellitus, Glc: Glucose, HOMA IR: Homeostasis Model Assessment of IR, QUICKI: Quantitative Insulin sensitivity Check Index, MDRD: Modification of Diet in Renal Disease, BMI: Body Mass Index,

¹ patients not on statin (N=322, 80.5%)

Table 2. Antihypertensive treatment in controlled and uncontrolled treated hypertensive rheumatoid arthritis patients

	Total (N=171)	controlled HTN (N=37)	uncontrolled HTN (N=134)	p value
thiazide diuretic n(%)	78 (45.9)	19 (51.4)	59 (44.4)	NS
frusemide n(%)	16 (9.4)	2 (5.4)	14 (10.5)	NS
beta blocker HTN n(%)	47 (27.6)	10 (27)	37 (28.7)	NS
beta blocker sum n(%)	61 (35.9)	12 (32.4)	49 (36.8)	NS
ace inhibitors/ARBs n(%)	102 (60)	17 (45.9)	85 (63.9)	0.049
dihydropyridine CCBs	41 (24.1)	6 (16.2)	35 (26.3)	NS
non dihydropyridine CCBs n(%)	6 (3.5)	0 (0)	6 (4.5)	NS
CCBs sum n(%)	46 (27.1)	6 (16.2)	40 (30.1)	NS
central blocker antihypertensives n(%)	5 (2.9)	1 (2.7)	4 (3)	NS
a-adrenoreceptor blockers n(%)	9 (5.3)	2 (5.4)	7 (5.3)	NS

beta blockers HTN: beta blockers used for indication hypertension

beta-blockers sum: used also for rate control, heart failure, angina, post myocardial infarction

ARBs: Angiotensin Receptor Blockers, CCBs: Calcium Channel Blockers




Figure 1. Increased prevalence of uncontrolled hypertension in older Rheumatoid Arthritis (RA) patients.




Figure 2. Increased prevalence of uncontrolled hypertension in Rheumatoid Arthritis (RA) patients with increased Body Mass Index (BMI)

Key messages:

- Hypertension is highly prevalent in RA patients
- Hypertension is under-diagnosed mainly in young RA patients and under-treated mainly in the older patients with co morbid cardiovascular disease
- Aggressive strategies for screening, treatment and monitoring of hypertension are required for the RA population

